News

Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

October 27, 2021

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the Events & Presentations section. The call will also be available by dialing 844-287-7410 (U.S.) or 914-800-3942 (International) five to ten minutes prior to the start time, using the passcode: 6837927.

About Sight Sciences
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world’s most prevalent eye diseases. The company currently markets two products, the OMNI® Surgical System and the TearCare® System. For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
© 2021 Sight Sciences. All rights reserved.

Media contact:
Shay Smith
Health+Commerce
707.971.9779
shay@healthandcommerce.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com

In The Media
December 19, 2024
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options Read More
November 19, 2024
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference Read More
November 7, 2024
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance Read More
November 7, 2024
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations Read More
October 18, 2024
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024 Read More
October 14, 2024
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial Read More
August 20, 2024
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference Read More
August 1, 2024
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance Read More
July 18, 2024
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 Read More
June 10, 2024
Sight Sciences Announces the Release of its First Sustainability Report Read More

Want to speak to one of our representatives?

Contact Us